We count on our employees and their abilities. To improve our patients’ quality of life. Our extensive expertise is the prerequisite for our long-term business success.
CREATING A FUTURE WORTH LIVING. FOR PATIENTS. WORLDWIDE. EVERY DAY.
Decades of experience, innovative research, the global leader in dialysis services and products – that is Fresenius Medical Care.

Patients with kidney disease can now look ahead with much more confidence thanks to our innovative technologies and treatment concepts. We give them a future, one that offers them the best possible quality of life. The increasing demand for modern dialysis methods forms the basis for us, as a leading provider in this area, to grow sustainably. Together with our employees, we focus on pursuing strategies that will enable us to continue our technological leadership. As a vertically integrated company, we offer products and services for the entire dialysis value chain.

The highest medical standards are our benchmark. This is our commitment to our patients, our partners in the health care system and our investors, who trust in the reliable performance and the future of Fresenius Medical Care.
“We keep on applying our knowledge and experience to help patients all over the world.”

RICE POWELL
CEO and Chairman of the Management Board
37 production sites worldwide

109,319 employees as of December 31, 2016

17,911 $M revenue in 2016
Every 0.7 seconds, we treat a patient with dialysis.
We performed 46.53 M dialysis treatments in 2016.

Dialysis is a vital blood cleansing procedure that substitutes the function of the kidney in case of kidney failure.

As a vertically integrated company, Fresenius Medical Care offers products and services along the entire dialysis value chain from a single source.

Along with our core business, we will focus on expanding our range of additional medical services.
~ 3.0 M
patients worldwide regularly receive a dialysis treatment.

~ 140 M
dialyzers were produced in 2016.

2. One in two dialysis machines worldwide is made by Fresenius Medical Care.
Fresenius Medical Care provides more people than ever with access to life-saving dialysis therapies. We will keep on working to expand our core business with dialysis products and the treatment of dialysis patients. Along with strong growth in our core business, we aim to expand our range of additional medical services, the so-called Care Coordination business.

The quality of our products and services makes us a reliable partner for patients, health care systems and investors.
Dialysis Products

HEMODIALYSIS (HD)  PERITONEAL DIALYSIS (PD)

Dialysis Services

Fresenius Medical Care is the leading provider of dialysis services treating 308,471 patients in 2016.

Care Coordination

The patient comes first

Coordinated delivery of pharmacy services
Vascular, cardiovascular and endovascular speciality services
Non-dialysis laboratory testing services
Health plan services

Ambulatory surgery center services
Hospitalist and intensivist services
Urgent care services
Physician practice services
### Revenue in $M

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>17,911</td>
<td>16,738</td>
</tr>
</tbody>
</table>

**Change of:** +7%

### Operating Income (EBIT) in $M

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2,638</td>
<td>2,327</td>
</tr>
</tbody>
</table>

**Change of:** +13%

### Selected Key Figures in $M

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Earnings before interest, taxes, depreciation and amortization (EBITDA)</td>
<td>3,413</td>
<td>3,044</td>
</tr>
<tr>
<td>Net cash provided by (used in) operating activities</td>
<td>2,140</td>
<td>1,960</td>
</tr>
<tr>
<td>Free cash flow&lt;sup&gt;2&lt;/sup&gt;</td>
<td>1,128</td>
<td>1,025</td>
</tr>
<tr>
<td>Capital expenditures, net</td>
<td>1,012</td>
<td>935</td>
</tr>
<tr>
<td>Acquisitions and investments, net</td>
<td>367</td>
<td>66</td>
</tr>
<tr>
<td>Operating income margin in %</td>
<td>14.7</td>
<td>13.9</td>
</tr>
<tr>
<td>Return on invested capital (ROIC) in %</td>
<td>7.8</td>
<td>7.0</td>
</tr>
<tr>
<td>Equity ratio (equity/total assets)&lt;sup&gt;3&lt;/sup&gt; in %</td>
<td>42.5</td>
<td>41.4</td>
</tr>
</tbody>
</table>

1. Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA.
2. Net cash provided by (used in) operating activities after capital expenditures, before acquisitions and investments.
3. As of December 31 of the respective year. 2015: In accordance with ASU 2015-17 (Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes) as of December 31, 2015 deferred taxes previously recorded in current assets and liabilities have been reclassified to noncurrent assets and liabilities in the amount of $216 M and $36 M, respectively. As a result of deferred tax netting, noncurrent assets and liabilities were then adjusted in the amount of $168 M.
REVENUE 2016

17,911 $ M

- 15% Europe, Middle East, Africa
- 9% Asia-Pacific
- 4% Latin America
- 72% North America

THEREOF HEALTH CARE SERVICES

14,519 $ M

- 4% Latin America
- 9% Europe, Middle East, Africa
- 5% Asia-Pacific
- 82% North America
- (19% thereof Care Coordination)

THEREOF DIALYSIS PRODUCTS

3,392 $ M

- 40% Europe, Middle East, Africa
- 27% Asia-Pacific
- 27% North America
- 6% Latin America
CREATING A FUTURE WORTH LIVING. 
BE A PART OF IT.

WE AIM:
TO OFFER OUR PATIENTS THE BEST AND SAFEST DIALYSIS PRODUCTS AND HEALTH CARE SERVICES
http://career.freseniusmedicalcare.com

EMPLOYEES BY REGION

- 8% Latin America
- 15% Corporate
- 17% Europe, Middle East, Africa
- 8% Asia-Pacific
- 52% North America

109,319
DIVIDEND PER SHARE IN €

<table>
<thead>
<tr>
<th>Year</th>
<th>Dividend per Share</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>0.96*</td>
</tr>
<tr>
<td>2015</td>
<td>0.80</td>
</tr>
<tr>
<td>2014</td>
<td>0.78</td>
</tr>
<tr>
<td>2013</td>
<td>0.77</td>
</tr>
<tr>
<td>2012</td>
<td>0.75</td>
</tr>
</tbody>
</table>

*Proposal to be approved by the Annual General Meeting on May 11, 2017.

SHARE PRICE PERFORMANCE – 5 YEARS IN €

<table>
<thead>
<tr>
<th>Year</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>90</td>
<td>80</td>
<td>70</td>
<td>60</td>
<td>50</td>
</tr>
</tbody>
</table>

BASIC SHARE DATA

Ticker symbols
- Frankfurt Stock Exchange/Prime Standard: FME
- New York Stock Exchange (NYSE): FMS
- Reuters: XETRA/ADR NYSE: FMEG.DE/FMS.N
- Bloomberg: XETRA/ADR NYSE: FME GY/FMS US

Security identification codes
- WKN: 578580
- ISIN: DE0005785802
- CUSIP No. (NYSE): 358029106
FINANCIAL CALENDAR

May 3, 17
Report on the first quarter 2017

May 11, 17
Annual General Meeting
Frankfurt am Main, Germany

May 16, 17
Payment of dividend subject to the approval of the Annual General Meeting

Aug 1, 17
Report on the second quarter 2017

Nov 2, 17
Report on the third quarter 2017

Subject to change.

IMPRINT

PUBLISHED BY
Fresenius Medical Care AG & Co. KGaA

EDITORIAL OFFICE
Investor Relations & Corporate Communications

EDITORIAL DEADLINE
March 8, 2017

CONCEPT AND DESIGN
hw.design gmbh